{"id":410495,"date":"2021-01-07T09:25:10","date_gmt":"2021-01-07T14:25:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=410495"},"modified":"2021-01-07T09:25:10","modified_gmt":"2021-01-07T14:25:10","slug":"first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/","title":{"rendered":"First patient in treatment in RhoVac’s clinical phase IIb study in United Kingdom"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n STOCKHOLM<\/span>, Jan. 7, 2021<\/span> \/PRNewswire\/ — RhoVac AB (“RhoVac”) announces today, on January 7<\/span>th<\/sup>, 2021, that the first patient in United Kingdom<\/span> is enrolled in the company’s clinical phase IIb study in prostate cancer, a study named RhoVac-002 (“BRaVac”).<\/b><\/p>\n

The first patient in United Kingdom<\/span> is enrolled in the clinical study, called BRaVac. This clinical trial phase IIb-study is a randomized, placebo controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent treatment. The clinical phase IIb study is an international, multicenter study, which will recruit over 175 patients in six European countries (Denmark<\/span>, Finland<\/span>, Sweden<\/span>, Belgium<\/span>, Germany<\/span> and United Kingdom<\/span>) and the US.<\/p>\n

\n CEO Anders M\u00e5nsson<\/span> comments:<\/b>\u00a0“We are very happy about the fact that, in spite of the pandemic, we have now been able to get all countries operational in the study”.<\/p>\n

This disclosure contains information that RhoVac is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596\/2014). The information was submitted for publication, through the agency of the contact person, on 07-01-2021<\/span>15:00 CET<\/span>.<\/p>\n

\n CONTACT: <\/b>\n <\/p>\n

\n For further information, please contact: <\/b>\n <\/p>\n

Anders M\u00e5nsson – CEO, RhoVac AB<\/p>\n

Phone number: +46 73-751 72 78<\/p>\n

E-mail: info@rhovac.com<\/a><\/p>\n

This information was brought to you by Cision http:\/\/news.cision.com<\/a><\/p>\n

\n https:\/\/news.cision.com\/rhovac\/r\/first-patient-in-treatment-in-rhovac-s-clinical-phase-iib-study-in-united-kingdom,c3264996<\/a>\n <\/p>\n

The following files are available for download:<\/p>\n

\n\n\n
\n

\n
\n https:\/\/mb.cision.com\/Main\/13747\/3264996\/1356856.pdf<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Release<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom-301202827.html<\/a><\/p>\n

SOURCE RhoVac<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire STOCKHOLM, Jan. 7, 2021 \/PRNewswire\/ — RhoVac AB (“RhoVac”) announces today, on January 7th, 2021, that the first patient in United Kingdom is enrolled in the company’s clinical phase IIb study in prostate cancer, a study named RhoVac-002 (“BRaVac”). The first patient in United Kingdom is enrolled in the clinical study, called BRaVac. This clinical trial phase IIb-study is a randomized, placebo controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent treatment. The clinical phase IIb study is an international, multicenter study, which will recruit over 175 patients in six European countries (Denmark, Finland, Sweden, Belgium, Germany … <\/p>\n

Continue reading “First patient in treatment in RhoVac’s clinical phase IIb study in United Kingdom”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-410495","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFirst patient in treatment in RhoVac's clinical phase IIb study in United Kingdom - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire STOCKHOLM, Jan. 7, 2021 \/PRNewswire\/ — RhoVac AB (“RhoVac”) announces today, on January 7th, 2021, that the first patient in United Kingdom is enrolled in the company’s clinical phase IIb study in prostate cancer, a study named RhoVac-002 (“BRaVac”). The first patient in United Kingdom is enrolled in the clinical study, called BRaVac. This clinical trial phase IIb-study is a randomized, placebo controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent treatment. The clinical phase IIb study is an international, multicenter study, which will recruit over 175 patients in six European countries (Denmark, Finland, Sweden, Belgium, Germany … Continue reading "First patient in treatment in RhoVac’s clinical phase IIb study in United Kingdom"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-07T14:25:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO40071&sd=2021-01-07\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"First patient in treatment in RhoVac’s clinical phase IIb study in United Kingdom\",\"datePublished\":\"2021-01-07T14:25:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\\\/\"},\"wordCount\":269,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO40071&sd=2021-01-07\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\\\/\",\"name\":\"First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO40071&sd=2021-01-07\",\"datePublished\":\"2021-01-07T14:25:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO40071&sd=2021-01-07\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO40071&sd=2021-01-07\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First patient in treatment in RhoVac’s clinical phase IIb study in United Kingdom\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/","og_locale":"en_US","og_type":"article","og_title":"First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom - Market Newsdesk","og_description":"PR Newswire STOCKHOLM, Jan. 7, 2021 \/PRNewswire\/ — RhoVac AB (“RhoVac”) announces today, on January 7th, 2021, that the first patient in United Kingdom is enrolled in the company’s clinical phase IIb study in prostate cancer, a study named RhoVac-002 (“BRaVac”). The first patient in United Kingdom is enrolled in the clinical study, called BRaVac. This clinical trial phase IIb-study is a randomized, placebo controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent treatment. The clinical phase IIb study is an international, multicenter study, which will recruit over 175 patients in six European countries (Denmark, Finland, Sweden, Belgium, Germany … Continue reading \"First patient in treatment in RhoVac’s clinical phase IIb study in United Kingdom\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-07T14:25:10+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO40071&sd=2021-01-07","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"First patient in treatment in RhoVac’s clinical phase IIb study in United Kingdom","datePublished":"2021-01-07T14:25:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/"},"wordCount":269,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO40071&sd=2021-01-07","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/","name":"First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO40071&sd=2021-01-07","datePublished":"2021-01-07T14:25:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO40071&sd=2021-01-07","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO40071&sd=2021-01-07"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-in-treatment-in-rhovacs-clinical-phase-iib-study-in-united-kingdom\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"First patient in treatment in RhoVac’s clinical phase IIb study in United Kingdom"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=410495"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410495\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=410495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=410495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=410495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}